Podcasts about Novo Nordisk

This Special Episode on Atrial Fibrillation covers: Cardiology this Week: A concise summary of recent studies Atrial fibrillation burden: clinical relevance of a new outcome Pulsed field ablation: game changer? Drug treatment following atrial fibrillation ablation Spotlight: Holiday Heart Syndrome Host: Rick Grobbee Guests: Rick Grobbee, Konstantinos Koskinas, Jason Andrade, Arian Sultan, Michiel Rienstra Want to watch that special episode? Go to: https://esc365.escardio.org/event/2549 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Jason Andrade, Yasmina Bououdina, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Michiel Rienstra has declared to have potential conflicts of interest to report: consultancy fees from Bayer (OCEANIC-AF national PI) , InCarda Therapeutics (RESTORE-SR national PI), Novartis to the institution. Speaker fee from Daiichi-Sankyo, Pfizer to the institution. Unrestricted research grant from the Dutch Heart Foundation and is conducted in collaboration with and supported by the Dutch CardioVascular Alliance, 01-002-2022-0118 EmbRACE. Unrestricted research grant from ZonMW and the Dutch Heart Foundation; DECISION project 848090001. Unrestricted research grants from the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation; RACE V (CVON 2014–9), RED-CVD (CVON2017-11). Unrestricted research grant from Top Sector Life Sciences & Health to the Dutch Heart Foundation (PPP Allowance; CVON-AI (2018B017). Unrestricted research grant from the European Union's Horizon 2020 research and innovation programme under grant agreement; EHRA-PATHS (945260). This research is funded by the Dutch Heart Foundation and is conducted in collaboration with and supported by the Dutch CardioVascular Alliance, 01 -002 -2022 -0118 EmbRACE.  Emma Svennberg has declared to have potential conflicts

On today's show: A Correction: cat hair was found in diabetes drugs, not vaccines. Novo Nordisk's $16.5 billion acquisition Catalent — FDA contamination at the Indiana facility.Your host Crystal is a former clinical trials manager who read a Form 990 recreationally, and it ruined her life. Today we're doing a forensic accounting of nothing.THE MORGELLONS RESEARCH FOUNDATION IRS FILINGSThe Morgellons Research Foundation (MRF), "founded" by Mary Leitao, filed IRS Form 990 returns showing zero program service expenses. Not low. Zero.2004 Form 990: $318 in contributions. $0 expenses.2005 Form 990: $0 program expenses.2006 Form 990: Missing. This is the peak year — national TV, maximum donations, phones ringing. That return has never been located. Revenue reported retroactively: ~$29,000.MRF's sole named grant recipient was Thornton/Thorstensen Labs. Operator Michael Carlson was later indicted on 51 counts of falsifying test results. The lab was already decertified by the time the grant was granted. The MRF patient registry — real people, real names — has never been accounted for. No response to date from 2.23.26 open records request to OHSU.THE DOMAINmorgellons.org was registered March 14, 2002 by dkornsin@hotmail.com — not Mary Leitao, not any board member. That registrant possibly links to 2345.com, Chinese software infrastructure. Earliest site capture (June 5, 2002) lists a California fax number, contact morgellons@aol.com, and web designer Amy DiFerrari.DOUGLAS EWING BUCKNER SR —Fake DOCTORDouglas Buckner is listed as Vice President of the MRF board and identified as “Dr. Douglas Buckner PhD” on federal tax documents, in the Washington Post Magazine, and on Coast to Coast AM (February 2005). He is not a doctor. No MD. No PhD. No dissertation, residency, license, or verifiable work history. Born July 1946, Tennessee. Lived in Waycross, Georgia 35 years. Now on his father's land in Montgomery County, Tennessee. Bankruptcy filing, tax lien on record. His wife Janelle Fossen is the MRF board secretary. Two board seats, one household.On the 2005 Coast to Coast broadcast, host George Noory calls him a physician and Doctor repeatedly. Buckner never corrects him. He describes Morgellons symptoms accurately but frames the fibers as visually bizarre. They're not — they look like common textile fibers. The actual anomaly is fibers embedded under intact skin and emerging from wounds. The paranormal framing is intentionally discrediting perhaps, guilty as charged. KENNETH COWLES — DIED IN HIS SLEEP AT 53Kenneth Cowles served as MRF Director of PR and Media, unpaid. Day job: production assistant on Guiding Light. He says he found Morgellons by sending a mass email looking for a story and hearing back from a woman in Tacoma, Washington. Didn't believe her at first. Eventually did. That led him to Mary Leitao.From a soap opera set, Cowles placed Morgellons on KTVU Fox San Francisco, stations in Reno and Houston, and in 2006 on ABC News prime time and NBC. Correction: the rumored $10,000 plane ticket to Tulsa and $2,000 phone bill were Kenneth Cowles, not Dale Cowler.Kenneth Cowles died October 2007, age 53. “Peacefully in his sleep,” per Mary Leitao. Forty-eight days after Charles E. Holman, former MRF chairman, died at 54. Holman had asked Mary for access to the financial statements and was refused. Mary's husband Edward Leitao died at 54 of cardiac arrest months before she incorporated the MRF. Three men connected to this foundation. All dead in their 50s. Nobody wrote about it.MRF BOARD: William T. Harvey (chairman, NASA), Mary Leitao (founder), Douglas Buckner (VP, not a doctor), Dale Cowler (CPA/treasurer), Janelle Fossen (secretary, Buckner's wife), Kenneth Cowles (PR, deceased), Charles E. Holman (former chair, deceased).OSU open records request 26-100 filed February 23, 2026 — no response. Death certificates not known for Edward Leitao, Charles Holman, Kenneth Cowles.moremorgellons.com

In this deep dive, Zaid breaks down how Hims became one of the hottest stocks in the market during the GLP-1 boom, and why the company suddenly found itself in the middle of an FDA crackdown and a legal fight with Novo Nordisk. He also dives into the bull case, the bear case, and whether Hims can actually build a lasting digital healthcare business from here.

In this week’s episode of “The Top Line,” we take a deep dive into the fourth-quarter performance of the biopharma industry and how the sector fared in 2025 overall. As the world’s 25 largest biopharma companies reported earnings, attention quickly shifted to their outlook for 2026. Only five drugmakers expect faster growth than in 2025, and some are projecting sales declines. One of the most surprising outlooks came from Novo Nordisk, which expects a significant drop in sales. Several other companies are also facing the loss of patent protection for blockbuster drugs, leading them to forecast either declining revenue or slower growth. Fierce Pharma’s Kevin Dunleavy and Eric Sagonowsky discuss the trends emerging from fourth-quarter earnings and how the industry’s performance compares with previous quarters. They also examine the intensifying GLP-1 competition between Novo Nordisk and Eli Lilly and how the two companies appear to be heading in opposite directions. To learn more about the topics in this episode: Eli Lilly, Novo Nordisk lead revenue boom in the 'always tricky' Q4 As Lilly flourishes in Q4, peer projections signal looming sector slowdown in 2026 Biopharma industry gathers momentum in Q3 In Q3, drugmakers saw a marked decline in US vaccine sales as Eli Lilly kicked into higher gear See omnystudio.com/listener for privacy information.

In this episode of The Gist Healthcare Podcast, we cover the FDA's top vaccine official stepping down, a federal ruling involving Leapfrog and Tenet hospitals, and a new agreement between Novo Nordisk and Hims and Hers. Hosted on Acast. See acast.com/privacy for more information.

Newly-minted Nobel laureate Fred Ramsdell joins Claudia to discuss his groundbreaking work on regulatory T cells, which act as the immune system's natural "brakes." His research aims to "reset" the immune system to cure autoimmune diseases (like rheumatoid arthritis and MS) moving beyond mere symptom management. Fred reflects on his new role as a science advocate, addressing the crisis of public trust in science and the need for greater diversity in biomedical research.During this conversation, recorded at the UC Berkeley/JP Morgan Healthcare Conference in Taipei, Claudia and Fred discuss:How Fred missed the Nobel Prize call while off-grid campingHis shifting goals in retirement post Nobel winWhy he chose biotech: collaboration, speed, and being "wrong fast"The deeper threat to science: funding vs. trust, and his surprise in SwedenFred says he's excited to see what other advances are possible in what he calls “the early innings” of scientific discovery:“As humans, we're really good at solving technological problems. If we know what the problem is, historically, we're pretty good at figuring out an answer. [We're] pretty confident now that we know the problem in peripheral tolerance, that is the breakdown of our immune system recognizing our own tissues. Now we know what at least part of that problem is, we'll be able to engineer our way into a solution.”Relevant LinksSee more about Fred's Nobel win and read the UCLA press releaseFred's Nobel prize lectureSee Fred and his co-laureates accept their prizeRead more about Fred's 2025 co-laureates Mary E. Brunkow and Shimon SakaguchiAbout Our GuestFred Ramsdell, PhD, is a veteran biotechnology leader in immunology with nearly three decades of experience and was named a winner of the 2025 Nobel Prize in Physiology or Medicine. A co-founder of Sonoma Biotherapeutics, Dr. Ramsdell was the former Chief Scientific Officer (CSO) and current Scientific Advisory Board Chair of the Company.Dr. Ramsdell earned his doctoral degree in microbiology and immunology from the University of California, Los Angeles and holds a bachelor's degree in biochemistry and cell biology from the University of California, San Diego. Following a fellowship at the NIH, Dr. Ramsdell joined Immunex studying T cell activation and tolerance, with a focus on gene discovery and functional characterization. He later joined Darwin Molecular (which was later acquired by Celltech R&D) to establish the immunology program. Amongst other programs, he led the team that discovered and characterized FoxP3, a gene critical to the function of regulatory T cells. Dr. Ramsdell joined ZymoGenetics in 2004, where he led teams studying novel proteins with potential regulatory activity in lymphoid cells. In 2008, Novo Nordisk brought on Dr. Ramsdell to help establish the company's new Inflammation Research Center in Seattle and lead the Immunobiology group. Prior to SonomaBio, Dr. Ramsdell was the CSO at the Parker Institute for Cancer Immunotherapy (PICI) where he helped to build and advance multiple research programs from the inception of the Institute.SourceConnect With UsFor more information on The Other 80 please visit our website - www.theother80.com. To connect with our team, please email claudia@theother80.com and follow us on twitter @claudiawilliams and LinkedInSubscribe to The Other 80 on YouTube so you never miss our video extras or special video episodes!

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über einen Warnschuss für Novo Nordisk, Amazons Mega-Emission und eine Dividendenperle mit Deindustrialisierungsgefahr. Außerdem geht es um Oracle, Verizon, AB Inbev, CVS, Microsoft, Meta, Nvidia, Vertiv, GE Vernova, Pershing Square, Berkshire Hathaway, Eli Lilly, NIO, Hugo Boss, Lufthansa, Bristol Myers Squibb, Astellas, Volkswagen, Audi, Stellantis, Ferrari. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

After Friday's news that Center for Biologics Evaluation & Research Chief Vinay Prasad will leave the FDA—again—at the end of April, stocks for several rare disease drug developers popped. UniQure, in particular, was up 51% in premarket trading on Monday. Prasad in a meeting last Thursday with select journalists called the biotech's Huntington's treatment AMT-130 a “failed” therapy, according to STAT News. Shares of Replimune and REGENXBIO—which have suffered rejections during the past year—also rose.One person who is not impressed with the plethora of rare disease drug rejections of late—H.C. Wainwright said in a note Tuesday that there have been at least five cell and gene therapies they believe could have been approved under prior FDA officials—is Wisconsin Senator Ron Johnson. Tuesday, Bloomberg News reported that Johnson has launched an investigation into these recent denials.Johnson called the FDA's request that uniQure conduct a sham surgery-controlled trial of AMT-130 “bureaucratic idiocy,” according to the publication. Meanwhile, uniQure and the FDA appear to be on different pages regarding the design of this prospective trial, with uniQure Chief Medical Officer Walid Abi-Saab referring to a 10-12 hour surgery during which [burr] holes would be drilled in patients' skulls and Prasad claiming on a media call last week that it would require only “one to three nicks in the scalp.”In other news, no episode of The Weekly would be complete without our weekly weight loss segment. Roche and Zealand Pharma's amylin analog fell short of Eli Lilly's rival candidate eloralintide; AbbVie reported what analysts called “competitive” results, with its amylin analog eliciting nearly 10% weight loss at 13 weeks in a Phase 1 trial; and Regeneron touted a much-needed Phase 3 win for Hansoh-partnered dual GLP-1/GIPR agonist olatorepatide in China. Beyond data, Novo Nordisk and Hims & Hers are together again, with Novo striking a deal to sell its injectable and oral GLP-1 medicines through the telehealth provider.Elsewhere on the business side of biopharma, experts are reporting a cut-throat atmosphere behind doors on the M&A front as the supply of companies available to buy dwindles.

It's In the News, a look at the top headlines and stories in the diabetes community. This week's top stories: Stem Cell Islet Therapy Partnership, "Lyla's Law" Type 1 Testing Debate, Patient-Led Insulin Dosing for Gestational Diabetes, $3 Semaglutide Manufacturing, FDA GLP-1 Compounding Crackdown Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom  All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  transcript with links:  Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. I am definitely feeling better – that lingering cold is gone – but whew still recovering from non stop travel for the past five weeks. I have a great strech of time her at home, then going to Vegas for Brekathorugh T1D at the end of the month and we have two club 1921 events in April – Atlanta and Philly. Before we jump into the news – I need your community commercials! These have been a lot of fun, I announced them late last year – your voice on the show. All the instructions it's very easy in the show notes. Okay.. our top story this week: XX A biotech company developing stem-cell treatments for type 1 diabetes has announced a new research partnership aimed at improving the survival of transplanted insulin-producing cells. NewcelX, a clinical-stage company based in Switzerland, said it will work with Eledon Pharmaceuticals to study a combination approach. The goal is to help transplanted cells survive longer in the body by reducing the immune response that often leads to transplant rejection. If successful, the strategy could support longer-lasting islet cell replacement and move the therapy closer to becoming a functional treatment for people with type 1 diabetes. However, the companies have not yet released any safety or effectiveness data on the combination treatment, and financial details of the partnership were not disclosed. The research agreement is focused on exploring whether combining stem-cell-derived islets with targeted immune therapy can lead to longer-lasting cell transplants and improved outcomes for people with type 1 diabetes. https://www.stocktitan.net/news/ELDN/newcel-x-announces-strategic-collaboration-with-eledon-d10l1vqdofls.html XX Debate this week in the UK on whether testing for type 1 diabetes should become mandatory when children present with symptoms. The Westminster Hall debate, scheduled for 9 March, will consider calls for routine testing of babies, toddlers and young children who show signs associated with the condition. It follows a petition backing the move, dubbed 'Lyla's Law', which passed 121,000 signatures in December 2025. The campaign was launched by John Story after his two-year-old daughter, Lyla, died from diabetic ketoacidosis (DKA) on 3 May 2025, 16 hours after being diagnosed with tonsillitis. https://www.nursinginpractice.com/clinical/diabetes-and-endocrinology/diabetes-community-urged-to-call-on-mps-to-attend-lylas-law-debate/ XX     A new study suggests that people with gestational diabetes who adjust their own insulin doses may reach healthy blood sugar levels faster than those whose doses are adjusted by clinicians. Half of the participants were assigned to adjust their own insulin doses using a simple rule: increase the dose by two units if fasting blood glucose was above 95 mg/dL, decrease it by two units if it dropped below 70 mg/dL, and keep the same dose if levels fell in between. The other half had their insulin adjusted by clinicians through weekly reviews. By the end of pregnancy, both groups had similar average fasting glucose levels before delivery: about 89 mg/dL in the patient-led group and 90 mg/dL in the clinician-led group. However, those adjusting their own insulin reached their blood sugar targets more quickly, averaging 1.8 weeks compared with 2.5 weeks for those managed by clinicians. The study also found lower risks of certain complications among the patient-led group. https://www.medscape.com/viewarticle/self-insulin-dosing-leads-control-gestational-diabetes-2026a1000729 XX   A blockbuster anti-obesity and diabetes drug could cost as little as $3 per month to manufacture once it goes off patent later this month, researchers said Friday, providing a major opportunity to boost health in low and middle-income countries.   Semaglutide, the active molecule in Novo Nordisk's Ozempic and Wegovy will lose patent protection in countries such as Brazil, China, and India later this month, and researchers identified 150 countries where it was never patented. These researchers estimated it will cost as little as $3 to produce a month's supply of semaglutide, which in its branded form sells for around $200 a month in the United States. Another of the study's authors, Professor Francois Venter at the University of Witwatersrand in South Africa, said drugs to treat HIV, TB, malaria, and hepatitis are now available at prices close to production costs but still sufficient for generic manufacturers to operate. https://www.sciencealert.com/weight-loss-drugs-could-cost-just-3-a-month-to-make-as-patents-end XX Here in the US the FDA is stepping up its efforts to combat widespread GLP-1 drug compounding. In its latest offensive, the agency has unleashed a fresh set of 30 warning letters targeting telehealth companies it says make "false or misleading" claims about compounded versions of popular obesity drugs. The FDA says Compounded drugs can be important for overcoming shortages or meeting unique patient needs—but compounders should not try to compound drugs in a way that circumvents FDA's approval process." https://www.fiercepharma.com/pharma/fda-ramps-crackdown-glp-1-drug-compounders-fresh-batch-30-warning-letters XX   Check your infusion sets for an issue: Unomedical, a subsidiary of Convatec and a supplier of insulin infusion sets to diabetes tech firms, has received a warning letter from the FDA. Inspectors raised concerns with leaking infusion sets, following a regulatory assessment of Unomedical's facility in Reynosa, Mexico, last summer. Unomedical supplies infusion sets to insulin pump makers including Medtronic, Tandem Diabetes Care and Beta Bionics. In a Feb. 3 statement, Convatec said the letter focuses on reporting procedures and quality protocols and does not place restrictions on producing, marketing or distributing any of Unomedical's products.  Unomedical told the FDA in its responses that it plans to conduct a retrospective review of complaints involving serious injury or death by January and conduct additional training on complaint handling by May.   https://www.medtechdive.com/news/fda-warns-insulin-infusion-set-maker-unomedical-over-leaks-mishandled-comp/813503/ XX Nearly four in ten people with type 2 diabetes do not take their medications as prescribed, according to a new research review published in Diabetologia in November 2025.   Researchers examined existing studies on medication adherence, including how often patients miss doses, why it happens, and what strategies may help. They estimated that about 38% of patients with type 2 diabetes are not fully adherent to their medications.   Adherence rates vary depending on the type of medication. About 63% to 68% of patients take oral glucose-lowering drugs as directed, while adherence drops to 43% to 54% for injectable GLP-1 medications and 41% to 64% for insulin.   Poor adherence can lead to serious consequences. One retrospective study cited in the review found that patients who consistently took their glucose-lowering medications had a 31% lower risk of hospitalization or emergency department visits.   The review also highlighted ways to improve adherence. Simplifying medication routines can help, such as using fixed-dose combination pills, which combine multiple drugs into a single tablet. Studies show these combinations are linked to better adherence and improved blood sugar control.   Pharmacists can also play an important role by providing education, reviewing medications, setting up reminders, and helping patients organize their treatment plans. The researchers noted that support should be tailored to each patient. Older adults may benefit from simpler systems and caregiver support, while younger patients may respond better to digital tools like app-based reminders.   The authors also found that measuring adherence is challenging and recommend using multiple methods, such as pharmacy records, patient interviews, and objective tests when possible.   Overall, the review concludes that personalized, multi-step approaches lasting at least three months are most effective in helping people with type 2 diabetes stay on track with their medications. https://www.pharmacytimes.com/view/type-2-diabetes-medication-adherence-rates-remain-low-and-pharmacists-can-help XX New clinical trial shows metformin does not directly reverse insulin resistance in people with type 1 diabetes. Instead, it lowers the total amount of insulin required to keep blood glucose levels within the recommended range. The findings, published in Nature Communications, challenge long-held assumptions about how metformin works in type 1 diabetes. The results may help physicians refine treatment strategies and reduce the daily demands placed on people who rely solely on insulin therapy. "Insulin resistance is a growing problem in type 1 diabetes. Not only does it make regulating blood sugar levels difficult, but it is an underappreciated risk factor for heart disease, which is one of the biggest causes of health complications and deaths in those with type 1 diabetes," says Dr. Jennifer Snaith, endocrinologist and co-lead of the study.   https://scitechdaily.com/groundbreaking-trial-reveals-unexpected-benefit-of-metformin-in-type-1-diabetes/   Tech news ahead, including updates from Sensonics, Dexcom & Tandem.. right after this…. Back ot the wnews.. XX Sensonics shares that it's secured FDA investigational device exemption (IDE) for its self-powered, battery-enabled Gemini sensor. It enrolled the first patients in the IDE trial and expects to complete that in the second half of 2026. Gemini builds on the implanted CGM to put the transmitter under the skin as well as the sensor. https://www.drugdeliverybusiness.com/senseonics-q4-2025-ide-gemini-cgm/ XX Medtronic Diabetes is now officially MiniMid, a stand alone public company. Medtronic  acquired MiniMed 25 years ago announed last May that it would spin its diabetes business off. In their statement the company points out that MiniMed is the only diabetes tech company to sell both insulin pumps and continuous glucose monitors.   https://www.investing.com/news/stock-market-news/medtronics-diabetes-unit-minimed-valued-at-53-billion-as-shares-fall-in-nasdaq-debut-4547518 XX Kevin Sayer heads back to Dexcom.. The former CEO is back in his position as executive chair of the Board, he'd stepped away for a medical leave. Dexcom (Nasdaq:DXCM) announced today in an SEC filing that former CEO Kevin Sayer has returned from his leave of absence. Sayer's return to the board comes just days after Dexcom announced a new board member. Last week, the company announced that it added Google SVP, Platforms and Devices, Rick Osterloh, to its board as well.     https://www.drugdeliverybusiness.com/kevin-sayer-returns-dexcom-board-chair/ SAN DIEGO - DexCom, Inc. (NASDAQ:DXCM) announced the appointment of Rick Osterloh to its Board of Directors, effective today, according to a press release statement.   Osterloh serves as Senior Vice President, Platforms & Devices at Google, where he oversees Android, Google Play, Chrome, and Google's hardware portfolio including Pixel phones, Google Nest devices, and Fitbit wearables. He has held this position since 2016.   https://www.investing.com/news/company-news/dexcom-appoints-google-executive-rick-osterloh-to-board-93CH-4529662 XX Sequel Med Tech announced broad national availability of its twiist™ Automated Insulin Delivery (AID) System powered by Tidepool. After U.S. FDA clearance in 2024 and a controlled launch to optimize the twiist experience, the system is now fully available nationwide. The release says: Built on Sequel's proprietary iiSure™ Technology, the system enables earlier detection of delivery issues, alerting users to blockages up to nine times faster than other AID systems1, potentially reducing the risk of unexplained high glucose and giving you time to take action before experiencing severe high blood sugar or DKA2. Designed to expand access to automated insulin delivery, twiist is available through pharmacy channels with a flexible access model, XX Tandem Diabetes Care's Mobi automated insulin delivery system is now available with Android devices. In November, Tandem announced that it received FDA approval for the Android version of its Mobi mobile app. The pump, which pairs with Tandem's Control-IQ+ algorithm, previously worked with iOS software. At the time of the clearance, it said it would commence a limited rollout before the full launch — now underway — this year.   Tandem launched Mobi in the U.S. in February 2024. It initially received FDA clearance for people with diabetes ages six and up in July 2023. The system then received expanded clearance for pediatric indications in April 2024, then later won CE mark in May 2025.   Mobi features a 200-unit insulin cartridge and an on-pump button to provide an alternative to phone control for insulin boluses. It comes in at less than half the size of the flagship Tandem pump system, the t:slim X2 pump. Mobi can fit in a coin pocket, clip to clothing or go on the body with an adhesive sleeve. https://www.drugdeliverybusiness.com/tandem-diabetes-care-launches-mobi-android/

March 10, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: Novo Nordisk drops patent case against Hims & Hers as companies reach agreement for Hims to offer FDA-approved Ozempic and Wegovy at standard pricing Whoop introduces hormone biomarker testing for 11 hormonal markers combined with wearable data and AI-driven insights as women become fastest-growing user segment Fitt Insider releases Scouting Report highlighting 50 early-stage startups shaping wellness across mental, physical, social, environmental, and existential health Today's episode is brought to you by AIIR — a modern communications and experiential agency for health, wellness, fitness, and performance brands. From earned media to events and creator-led campaigns, AIIR helps companies sharpen their story, earn attention, and build trust that compounds. Visit aiir.agency to learn more. More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über einen völlig verrückten Wochenstart an den Märkten, einen durchwachsenen Börsengang in Frankfurt und einen deutschen Maschinenbauer mit Zoll-Resilienz. Außerdem geht es um Alphabet, Amazon, American Airlines, Amgen, Apple, Barrick Gold, Biontech, Caterpillar, Chevron, Cisco, Coherent, ConocoPhillips, Corteva, CSG, Deere, Delta Air Lines, Echostar, Eli Lilly, ExxonMobil, Freeport-McMoRan, Gabler Group, Gea, HP Enterprise, Intuitive Surgical, Johnson & Johnson, Live Nation Entertainment, Lumentum, Meta, Microsoft, Mosaic, Newmont, Nordisk, Novo Nordisk, Nuccor, Nvidia, Occidental, Oracle, Pfizer, Powerus, Southern Copper, Southwest, T-Mobile, ThyssenKrupp, TKMS, United Airlines, Verizon, Vertiv, VW, Walmart. Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Stocks stage a major reversal as President Trump weighs in on the Iran War timeline, and where a top oil analyst sees the energy sector heading next after crude oil spikes above $100 per barrel. Plus, the latest on a Microsoft–Anthropic AI deal, Hims & Hers jumping on a new collaboration with Novo Nordisk, Bitcoin volatility below $70K, and shutdown-fueled airport delays snarling travel. Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

With the Iran war into its tenth day, Carl Quintanilla and Jim Cramer discussed a rough start to the week for stocks, with WTI Crude surging past $100/barrel for the first time since 2022. The anchors discussed navigating the markets in the wake of Middle East tensions, along with the spike in gasoline prices and how high they could go. Also in focus: President Trump's message on the oil price surge, credit concerns hit SoftBank shares, market bright spots, Oracle leads this week's earnings calendar, Hims & Hers soars on its agreement with Novo Nordisk.   Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

AP's Lisa Dwyer reports that Novo Nordisk is dropping it patent lawsuit against Hims & Hers.

There was plenty of drama on Wall Street today and that is where we'll start this evening. This is The Business News Headlines for Monday the 9th day of March and the day that would have been my Father's birthday.  I think of him daily. In other news, AI company Anthropic is suing the Trump Administration. In more legal news Novo Nordisk and Hims and Hers reach a deal.  Women and Uber made the news today. In more transportation news does Japan have the answer to an ailing train issue in Honolulu?  We'll talk about it.  Paris Hilton launches an effort to support female business owners following a disaster. We'll check the numbers in The Wall Street Report and it looks like the federal government will embark on a hiring binge.  Let's go. Thanks for listening! The award winning Insight on Business the News Hour with Michael Libbie is the only weekday business news podcast in the Midwest. The national, regional and some local business news along with long-form business interviews can be heard Monday - Friday. You can subscribe on  PlayerFM, Podbean, iTunes, Spotify, Stitcher or TuneIn Radio. And you can catch The Business News Hour Week in Review each Sunday Noon Central on News/Talk 1540 KXEL. The Business News Hour is a production of Insight Advertising, Marketing & Communications. You can follow us on Twitter @IoB_NewsHour...and on Threads @Insight_On_Business.

Market update for Monday March 9, 2026Check out the Public app for incredible investing tools and to support the show (LINK)Follow us on Instagram (@TheRundownDaily) for bonus content and instant reactions.In today's episode:Oil surpasses $100 a barrel Hims makes peace with Novo Nordisk Oracle & OpenAI bail on major data center planThe S&P 500 has some new entrantsAirline and cruise stocks dip amid oil price spike Fun fact: Pixar has its biggest opening weekend in nearly a decade

Welcome to Ozempic Weightloss Unlocked, the podcast where we decode what this powerful medication really means for your body, your health, and your everyday life.Today we are diving into the most important new research about Ozempic and other glucagon like peptide one weight loss drugs. These medicines were first used for diabetes, but they have rapidly become some of the most talked about tools for weight management and even heart health.According to the University of Cambridge, people who stop glucagon like peptide one drugs such as Ozempic and Wegovy regain, on average, about sixty percent of the weight they lost within one year of stopping. By around sixty weeks, the regain begins to level off and is projected to reach about seventy five percent of the lost weight. That means roughly a quarter of the original weight loss may stay off long term, even after the drug is stopped.Researchers suggest there are a few possible reasons. For some people, time on Ozempic seems to reset eating habits, like smaller portions and more balanced meals, and those behaviors can stick. There may also be longer lasting changes in hunger hormones and how the brain regulates appetite. But scientists still do not know exactly how much of the regained weight is fat versus muscle. Early data suggest that as much as forty to sixty percent of weight lost on these drugs can be lean mass, including muscle, and it is not yet clear if that muscle comes back in the same way.While the injectables have been the focus for years, the Association of American Medical Colleges reports that new glucagon like peptide one weight loss pills were prescribed to about one hundred seventy thousand people in the first three weeks after their United States launch in early twenty twenty six. Trial data from Novo Nordisk show that people taking the oral version with diet and activity changes lost about thirteen percent of their body weight over a little more than a year, compared with about fifteen to sixteen percent with injectable Wegovy. In practice, doctors say the results are broadly similar, and the big difference is convenience and preference. Some people find a pill easier than a weekly injection, even though the pill has strict empty stomach rules.Public health researchers at Johns Hopkins University report that glucagon like peptide one drugs lead to meaningful weight loss across age, race, and starting weight groups, although women in their study lost a somewhat higher percentage of body weight than men. At the population level, a recent Gallup poll cited by the Association of American Medical Colleges found that obesity rates in the United States have dipped slightly since these drugs became more common, suggesting they may already be shifting public health trends.At the same time, doctors are sounding a note of caution. The Association of American Medical Colleges highlights concerns about side effects, unequal access, and what happens when people use these medicines long term for many different conditions. Some clinicians are seeing new or worsened eating disorders, where people become intensely fearful of any weight regain after starting Ozempic. Others are worried about the possibility of losing too much muscle and what that might mean for strength, metabolism, and aging.The message from obesity and endocrine specialists is that Ozempic works best as part of a full plan, not a stand alone fix. That means nutrition support, resistance exercise to protect muscle, realistic expectations about possible weight regain if the drug is stopped, and an individualized decision about whether treatment should be short term or ongoing.On future episodes of Ozempic Weightloss Unlocked, we will explore mental health effects, muscle versus fat loss, and how these medications are being studied for conditions like heart disease, liver disease, and even addiction.Thank you for tuning in to Ozempic Weightloss Unlocked. Be sure to subscribe so you never miss an update on the science and real life impact of Ozempic and related medications.This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

I veckans avsnitt pratar vi om psykologin runt en av Sveriges största folksjukdomar, obesitas. En kronisk och komplex sjukdom som följs av stigmatisering och fördomar. För många svenskar betraktar inte obesitas som en sjukdom, utan som ett personligt misslyckande. I dagens avsnitt pratar vi om varför och vad det får för konsekvenser för oss som individer och som samhälle – och vi har dessutom en gästexpert! Läkare Qim Malmqvist hjälper oss förstå hur hälsa och fördomar hänger ihop.Avsnittet är ett betalt samarbete med Novo Nordisk. Hosted on Acast. See acast.com/privacy for more information.

Howie and Harlan are joined by Yale School of Medicine neurologist Kevin Sheth to discuss how collaboration helps drive breakthroughs in brain health, including advances in detecting stroke and other neurological diseases earlier and more precisely. Harlan reflects on lessons from his family's recent experience navigating the healthcare system; Howie examines the expanding marketplace for GLP-1 weight-loss drugs and the challenges of ensuring safe and appropriate use. Show notes: The Family Perspective Cleveland Clinic: Percutaneous Coronary Intervention "What's the Difference Between a CCU and an ICU?" Kevin Sheth Alva Health Mayo Clinic: Stroke Video: Kevin Sheth at the Yale Innovation Summit Sandra Saldana, PhD, MBA "Buddy System"  NIH: Multiple Principal Investigators "Assessing the Decade of the Brain" "Cerebrospinal fluid and plasma biomarkers in Alzheimer disease" Kevin Sheth: "Burden of Ischemic and Hemorrhagic Stroke Across the US From 1990 to 2019"  Endovascular Thrombectomy (EVT) Ischemic vs Hemorrhagic Stroke "What is cognitive reserve?"  Cheaper Obesity Drugs "Will Novo Nordisk's slashing of obesity drug prices save patients' money? It depends"  "Novo Nordisk to halve US list price of Wegovy from 2027"  "Walgreens Virtual Healthcare Adds Weight Management Services to Support Patients on Their Weight Loss Journey"  In the Yale School of Management's MBA for Executives program, you'll get a full MBA education in 22 months while applying new skills to your organization in real time. Yale's Executive Master of Public Health offers a rigorous public health education for working professionals, with the flexibility of evening online classes alongside three on-campus trainings. Email Howie and Harlan comments or questions.

Host: Sabiha Gati Guest: Thomas F. Luescher Want to watch that extended interview on The future of guidelines in an era of Big Data and AI, go to: https://esc365.escardio.org/event/2556?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/2556 Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode.  The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Sabiha Gati, Nicolle Kraenkel and Thomas F. Luescher have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology this Week: A concise summary of recent studies The future of guidelines in an era of big data and AI Exercise in hypertrophic cardiomyopathy Snapshots Host: Sabiha Gati Guests: Kostas Koskinas, Thomas F. Luescher, Michael Papadakis, Stephan Achenbach Want to watch that episode? Go to: https://esc365.escardio.org/event/2556 Want to watch the extended interview on The future of guidelines in an era of Big Data and AI, go to: https://esc365.escardio.org/event/2556?resource=interview Disclaimer: ESC TV Today is supported by Novartis through an independent funding. The programme has not been influenced in any way by its funding partner. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode.  The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Sabiha Gati, Nicolle Kraenkel and Thomas F. Luescher have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada.  Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that highlight the intricate interplay of scientific innovation, regulatory dynamics, and strategic maneuvers shaping the industry.Starting with Moderna, the company has reached a pivotal resolution in a long-standing patent dispute involving its mRNA-based COVID-19 vaccine, Spikevax. This settlement involves a hefty $950 million payout to Genevant Sciences and Arbutus Biopharma, resolving claims of patent infringements. This agreement underscores the complex nature of intellectual property in the rapidly evolving mRNA landscape. Securing patent rights is crucial as new vaccines and therapies are developed, and this resolution not only clears a legal hurdle for Moderna but also exemplifies the industry trend towards resolving such disputes to foster continuous innovation.Sanofi has embarked on a significant strategic move by entering a $1.53 billion global licensing deal with Sino Biopharmaceutical. This agreement secures rights to a first-in-class JAK/ROCK inhibitor, which shows promise in treating hematological and immunological conditions. Such collaborations reflect the increasing focus on innovative therapies that target complex biological pathways, highlighting how companies are seeking unique assets to bolster their competitive edge.Regulatory scrutiny continues to be a formidable theme in the industry. The FDA has intensified its oversight on compounded GLP-1 drugs, issuing 30 warning letters to telehealth companies marketing unauthorized versions. This action highlights the agency's commitment to ensuring drug safety and efficacy while emphasizing the challenges companies face in navigating regulatory landscapes for compounded medications. Additionally, Novo Nordisk has been cautioned by the FDA regarding advertising practices for GLP-1 receptor agonists, illustrating the ongoing regulatory focus on pharmaceutical marketing strategies and compliance standards.Meanwhile, Bayer is experiencing a period of resilience in its pharmaceutical division, driven largely by its cancer drug Nubeqa and cardiovascular agent Kerendia. Despite these successes, Bayer faces challenges as revenues from older drugs like Xarelto and Eylea decline. This scenario reflects a broader industry challenge where companies must innovate while managing mature product lines facing generic competition.Teva Pharmaceuticals is making strategic strides by securing a $400 million deal with Blackstone to develop an anti-TL1A antibody for inflammatory bowel disease (IBD), in partnership with Sanofi. This investment highlights continued interest in autoimmune and inflammatory conditions as lucrative targets for novel therapies. Financial partnerships like Teva's substantial agreement with Blackstone illustrate how such collaborations can support sustained R&D efforts in chronic disease management.Technological integration into healthcare is expanding rapidly, with Nvidia collaborating with Droplet Biosciences to explore AI applications in medtech and cancer research. These partnerships illustrate an industry shift towards leveraging artificial intelligence to enhance diagnostic capabilities and accelerate research efforts. Moreover, collaborations leveraging AI/ML technologies across drug discovery pipelines are gaining traction; Earendil Labs partnering with WuXi XDC exemplifies this trend alongside Merck & Co.'s multi-year AI oncology data deal with Tempus—enhancing precision medicine capabilities while expediting therapeutic discoveries.In terms of funding new therapeutic areas, ARPA-H has announced a $158 million initiative aimed at developing medicines targeting the lymphatic system. This marks an exploration into less charted territories within physiological research that could yield transforSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant advancements and challenges shaping the pharmaceutical and biotech industries. The landscape continues to evolve with scientific breakthroughs, regulatory hurdles, and strategic alliances that have profound implications for drug development and patient care.Let's begin with Novo Nordisk's substantial investment of $500 million into an Ireland-based plant. This move reflects the ongoing demand for obesity treatments like Wegovy, a GLP-1 receptor agonist known for its efficacy in diabetes and weight management. The expansion aims to enhance production capabilities, particularly for markets outside the US, highlighting the global demand for such therapies. Recent studies in rodents suggest that GLP-1 medications may also support heart attack recovery by relaxing blood vessels, indicating broader cardiovascular benefits. This illustrates the multifaceted potential of GLP-1 receptor agonists beyond their primary indications.Turning to regulatory developments, the FDA has issued complete response letters to AstraZeneca and GSK, citing deficiencies in their data submissions. The feedback questions the data integrity of AstraZeneca's Saphnelo and the efficacy of GSK's Exdensur. These letters emphasize the importance of robust clinical evidence for achieving regulatory approval, underscoring the FDA's stringent standards. Such regulatory scrutiny highlights the necessity for pharmaceutical companies to ensure comprehensive and transparent data presentation.In strategic maneuvers within the industry, Esperion Therapeutics has acquired Corstasis Therapeutics for over $75 million, bringing the newly FDA-approved nasal spray Enbumyst into its portfolio. This acquisition illustrates ongoing consolidation trends aimed at diversifying product offerings and strengthening market positions in an increasingly competitive landscape.Meanwhile, DISC Medicine's decision to lay off 20% of its workforce following the FDA's rejection of a rare disease drug candidate underscores the volatility and risk inherent in drug development. This highlights the financial and operational challenges biotechs face when navigating complex regulatory pathways.Novo Nordisk and BioMarin have received FDA label expansions, allowing them to reach broader patient populations or offer additional therapeutic indications. Such expansions are crucial for enhancing treatment access and driving company growth. However, these advancements also reflect the challenges companies face in meeting evolving regulatory expectations while striving to expand their market footprint.Geopolitical tensions impact the industry as well, with companies closely monitoring employee safety and supply chain stability amid conflicts in regions like the Middle East. This situation highlights the vulnerabilities of global operations and underscores the need for robust contingency planning to maintain medicine access during crises.On the innovation front, Kyowa Kirin has discontinued its late-stage autoimmune disease program following cancer concerns linked to its anti-OX40 monoclonal antibody. This decision reflects the complexities of balancing innovative research with patient safety considerations. The discontinuation followed new cancer cases among participants receiving an anti-OX40 monoclonal antibody treatment, emphasizing the critical need for robust safety monitoring throughout the development process.Theravance Biopharma's substantial downsizing reflects similar challenges after a failed phase 3 trial for a blood pressure disorder drug led to significant corporate restructuring. This highlights how clinical setbacks can profoundly impact corporate strategy and employee livelihoods, serving as cautionary tales about resource investments required inSupport the show

The FDA is dominating the headlines once again thisweek.  Days after FDA Commissioner Marty Makary appeared to question uniQure's gene therapy candidate for Huntington's disease, the company revealed that the agency will require it to conduct a randomized, double-blind, sham surgery–controlled Phase 3 study. The FDA also published anothercomplete response letter (CRL), this one for REGENXBIO's gene therapy for Hunter syndrome. The rejection, sustained by the biotech early last month, was driven by issues with the study's population, controls and use of surrogate markers to measure efficacy, according to the document.  Meanwhile, regulatory experts have expressed concernsthat the FDA's circle of trust is shrinking, making many decisions feel like “fiat”—both in terms of individual drug applications and policy. The FDA has reportedly initiated a probe into complaints that a toxic workplace is fostered by CBER director Vinay Prasad, who is at the heart of many of these decisions. Finally, the biopharma industry continues to react to the agency's pivot from a requirement of two pivotal trials to one for approval, asking why now, what are the risks and what exactly the FDA expects from this one trial.   Still on the gene therapy front, Sarepta Therapeutics CEO Doug Ingram stepped down last week to spend more time with family as the company's muscular dystrophy mission hits home. Also during the company's fourth quarter earnings call, Sarepta projected that sales of its embattled Duchenne muscular dystrophy gene therapy Elevidys will be flat or down as far as 15% in 2026.  On the obesity front, Eli Lilly topped Novo Nordisk again in a weight loss trial, this time in a Lilly-sponsored study of patients with type 2 diabetes. But don't count Novo out yet. The company is actively seeking out new obesity assets, according to business development executive Tamara Darsow. Just last week, Novo linked with Boston'sVivtex to advance novel weight loss pills.Finally, check out BioPham Executive this week for a rundown of 2025's top-selling assets—spoiler: Merck's Keytruda held onto its crown as number one—and a story on former2seventy exec Chip Baird's new role as CEO of recently launched Poplar Therapeutics, which secured a $45 million series A extension this week.

Ich spreche hier über Aktien, in die ich selbst investiert bin und die ich tendenziell auch in einer Konsolidierungsphase weiter kaufen würde. Dadurch kann es natürlich wie eine Empfehlung klingen – das ist es jedoch nicht. Gleichzeitig macht es für euch wenig Sinn, wenn ich ständig nur um den heißen Brei herumrede oder ausschließlich allgemeine Marktbewegungen kommentiere. Davon gibt es ohnehin schon genug. Deshalb ist es wichtig, dass ihr den Disclaimer ernst nehmt: Das hier ist keine Aufforderung, an der Börse tätig zu werden. Ich stelle lediglich meinen persönlichen Standpunkt dar. Es ist mein Risiko – euer Risiko müsst ihr selbst bestimmen. Wer in Einzelaktien investiert, geht immer ein Risiko ein. Genau das sollte man sich immer wieder bewusst machen. Und deshalb wird zu Beginn gewissermaßen ein kleines „Schmerzensgeld“ fällig.
 ► Hole dir jetzt deinen Zugang zur brandneuen BuyTheDip App! Jetzt anmelden & downloaden: http://buy-the-dip.de
 ► An diese E-Mail-Adresse kannst du mir deine Themen-Wünsche senden: podcast@lars-erichsen.de
 ► Meinen BuyTheDip-Podcast mit Sebastian Hell und Timo Baudzus findet ihr hier: https://buythedip.podigee.io
 ► Schau Dir hier die neue Aktion der Rendite-Spezialisten an: https://www.rendite-spezialisten.de/aktion
 ► TIPP: Sichere Dir wöchentlich meine Tipps zu Gold, Aktien, ETFs & Co. – 100% gratis: https://erichsen-report.de/
 Viel Freude beim Anhören. Über eine Bewertung und einen Kommentar freue ich mich sehr. Jede Bewertung ist wichtig. Denn sie hilft dabei, den Podcast bekannter zu machen. Damit noch mehr Menschen verstehen, wie sie ihr Geld mit Rendite anlegen können.
 ► Mein YouTube-Kanal: http://youtube.com/ErichsenGeld
 ► Folge meinem LinkedIn-Account: https://www.linkedin.com/in/erichsenlars/
 ► Folge mir bei Facebook: https://www.facebook.com/ErichsenGeld/
 ► Folge meinem Instagram-Account: https://www.instagram.com/erichsenlars
 Die verwendete Musik wurde unter www.soundtaxi.net lizenziert. 
Ein wichtiger abschließender Hinweis: Aus rechtlichen Gründen darf ich keine individuelle Einzelberatung geben. Meine geäußerte Meinung stellt keinerlei Aufforderung zum Handeln dar. Sie ist keine Aufforderung zum Kauf oder Verkauf von Wertpapieren.
 Zum Zeitpunkt der Erstellung dieses Beitrags war der Autor, Lars Erichsen, in folgenden der besprochenen Finanzinstrumente selbst investiert: Novo Nordisk. Geplante Änderungen: Keine. Weitere Informationen entnehmen Sie bitte unserem Transparenzhinweis zum Umgang mit Interessenskonflikten: https://www.lars-erichsen.de/transparenz-und-rechtshinweis

In der heutigen Folge sprechen die Finanzjournalisten Daniel Eckert und Lea Oetjen über einen überraschenden Kurssprung bei Reedereien, einen Coup von Nvidia und eine Erholung beim Bitcoin. Außerdem geht es um Tui, Lufthansa, United Airlines, Delta Air Lines, American Airlines, Hensoldt, Renk, TKMS, Rheinmetall, Lockheed Martin, RTX Corporation, Northrop Grumman, Hapag-Lloyd, Maersk, Novo Nordisk, Coherent, Lumentum, BYD, Deutsche Telekom, Beiersdorf, Strategy, Coinbase, iShares MSCI World Energy Sector ausschüttend (WKN: A2PHCF), SPDR MSCI World Energy ETF thesaurierend (WKN: A2AGZ1), Euwax Gold 2 (WKN: EWG2LD) und Xetra-Gold (WKN: A0S9GB). Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Thomas von Erlach, Ph.D., Cofounder and CEO at Vivtex, a company spun out of the Langer Lab at MIT that's focused on developing orally available biologics. The company announced a deal in late February '26 with Novo Nordisk for up to $2.1 billion to develop next-gen oral drugs for obesity and diabetes, bringing the total number of Vivtex's partnerships to 10. Thomas shares his experiences working in the lab with Dr. Robert Langer, Ph.D., starting up Vivtex around his co-invention (a "GI tract on a chip"), building trust externally and securing the right partnerships, and using a strategic stealth period to refine Vivtex's platform technology before scaling it out. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

You can listen to the first episode of this three-part series here. GLP-1 medications to treat diabetes, obesity and several other illnesses have exploded in popularity since Ozempic was approved for use in Canada back in 2018. Ozempic and Wegovy, the GLP-1s which contain semaglutide, are the third-most prescribed drug in Canada, and by far the best-selling one. Chris Hannay, The Globe's business of health reporter, will explain why the introduction of generic semaglutide will mean lower prices and more options for Canadians. And we'll explore access to these drugs with The Globe's health reporter Kelly Grant on who gets their GLP-1 covered by their insurance – and who doesn't. Plus, Globe audio producer Kasia Mychajlowycz leads us on a journey to understand just how the virtual pharmacies advertised all over her social media feed are vetting people who want Ozempic prescriptions. The next episode and final episode of Skinny, Inc. is next Monday, March 9. You can contact the National Eating Disorders Information Centre at their toll-free hotline at 1-866-NEDIC-20 or visit their website. Questions? Comments? Ideas? E-mail us at thedecibel@globeandmail.com Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Some people do their best thinking on a walk. Me? I do my best thinking in the shower.   So I was thinking in the shower about how "The Most Interesting Man in the World" is back — yes, that guy, Jonathan Goldsmith, returning as the Dos Equis spokesperson after a ten-year hiatus, now with a funny "amnesia" twist and a whole lot of nostalgia. And while I do appreciate a sexy, wise older gentleman with an open collar and a "stay thirsty, my friends" vibe, my shower thoughts flowed to this thought: "Okay… but where is the campaign for "The Most Interesting WOMAN in the World?" Who the heck is SHE?  Because if we're being honest, she's probably not lounging around with a beer plotting her next adventure. She may be plotting but she's got a 'sh*tload of things to finish first before cracking open a beer or pouring a glass of wine or doing whatever relaxes her. So WHO IS SHE? By Jove I thought to myself, "The Most Interesting WOMAN in the World" is… WE!   WE meaning  – all the women over 50 (and there are plenty I tell ya!) with wisdom, passion and purpose —out there in the world 'still in the game', who've been there, done that, – and are still swinging against all odds most days. I was thinking, SHE likely has wrinkles, uses reading glasses, has a very busy brain, likely has a demanding job or business or demanding caretaking obligation. And most likely has a huge heart that still puts everyone else first. Hmmm. Sounds a lot like me. Sound like you? Or someone you know?  Oh - and she buys a boatload of stuff. Like Me. "The Most Interesting Woman in the World". Hmmm.  She's the woman who: might not have a giant social media following… but has massive word-of-mouth power buys everything for everybody (herself, the household, the kids, the grandkids, the nieces, the nephews… and probably the neighbor) is old-school but open to new things (especially if they promise better health, more energy, fewer annoyances or promise to make her look younger.) "The Most Interesting WOMAN in the World" Takes Risks!  Yes, she does! So who am I not to? Especially since I'm the one always pushing others to: "Risk It! or Regret It! I decided to RISK turning on my phone camera to record an opening segment of my radio show on 'video' as well as audio, so you could SEE what you usually don't when I do my live radio show. Yup, you can see how I talk with my hands and see the products I brought in from my house for 'show and tell' on the air that day. It was not a comfortable decision. I've been avoiding video. I do not love my looks these days, but I did it. And now I'm cool because I created a live radio show, that's partially on video, that's also a podcast, and has been turned into short media clips for other social media channels to drive back to the full video opening of my radio show on You Tube, that may encourage people to go and listen to the rest of the audio of my podcast - and maybe tune in live to the radio show. Full disclosure: All this effort did not burn a calorie. The live radio show is easy. I've been doing live radio so long I could do it in my sleep. It's all the other new pieces of the media pie - the audio /podcast /video/blog /social media puzzle, that takes quite an effort. I'll tell ya this much. AI filters are much cheaper than Botox, and figuring all this out was mentally exhausting. HOWEVER! "WE… "The Most Interesting Women In the World"  cannot stay interesting… if we do not embrace new knowledge and take new risks! Ok so …For fun I brought some products from my house to the radio studio that "The Most Interesting WOMAN in the World" might own for 'show and tell'.   Centrum Women 50+ MultiGummy (because we're doing our best to not fall apart like cheap patio furniture) Saline nasal spray (a product we somehow didn't grow up with but now feels like a household essential. Who knew. Right?) Lume deodorant 72-hour protection! (Once I got past the initial awkward TV commercial with the Founder focusing on where else this stuff can make me smell nice - I decided to just get on board for the 72 hours under my arms so I'd have one less thing to worry about - just in case I forgot.) A gadgety little YCZ Electric Massage Pro eye tool my daughter politely gave me as a gift to try and HELP me. (warm, glowy, red light-ish… fine fine we're trying new things!) Costco Italian Extra Virgin Olive Oil (because it's a BIG bottle of quality olive oil that tastes great straight from my peeps back in Italy at a great price. If I'm going to "do better," I want food that tastes like it loves me back) Morning Kick by Chuck Norris (I took his quiz, got labeled a "rapid ager," and immediately decided I need Chuck to back me freakin up. I'm testing it and kinda love it) Also, because of the nonstop flow of information these days I always come across a lot of 'who knew' stuff I find out that I want to share. Like that dry roasted peanuts build your telomeres. Yup. Short telomeres equal short life. So, I stole my Dave's peanuts for show and tell. He now brags he's younger because he eats them, and now I have to eat them just to have my telomeres catch up. (I tell ya being interesting is a nonstop sport.) And because "The Most Interesting Woman in the World" is also likely starting to blow some body parts… I showed off a flyer featuring that great gal Evelyn the physical therapist from ProClinix who's been workin' on me helping to get me get back in the game! (which starts with me getting on and off the table). And because "The Most Interesting Woman in the World" also wants to have as much fun as possible before she's dead… I also discussed just how many companies are pitching me to come have fun with them. Like the  Royal Caribbean cruise line that begs me by email almost daily to sail away with them again, and again, and again. YES, YES,  "The Most Interesting Woman in the World" – The collective 'WE' – want to have more FUN!   We're open. Where are we going?  We're IN! Just can't be the same day we're already booked. Like on a day we have a Dr. or dentist appointment or are taking someone else to a Dr. or a dentist appt. Can't be on a day when a plumber is coming to the house or on a day when we have an appointment, meeting, a zoom, going to a kids sports event or when we're babysitting. Oh, or when we've got a hair appt. And it can't be anything that starts too late at night or requires us to drive far in bad weather.   Other than we're free. LOL   Here's what I touched on the rest of the show The "anti-marketing" protein bar that's winning the protein wars is simply DAVID and why some brands win without screaming. Apparently, a protein bar called David is crushing it, partly because it's doing the opposite of what every loud, neon, influencer-filled protein brand is doing. Simple subway ads. Tons of white space. A sleek package. No drama. And the numbers? Wild. The brand's buzz has been building like a cult favorite, with big fundraising and serious sales projections. I first tasted them at a National Women's Pickleball Foundation event and immediately understood the strategy: get it in people's mouths first — then they'll come looking for it later. (That's marketing.) Then I found our there's a New personality label: "Otrovert"  "Wait… is that me?" Otrovert (from "otro," meaning "other") is basically someone who can look extroverted and function socially just fine…but actually recharges best alone or in quieter settings. Observant, sensitive to group dynamics, craving real connection… and sometimes leaving a room feeling oddly separate. The takeaway? Pressure's off. You're allowed to be social AND need silence. You're allowed to shine AND need downtime. Be who you are. (I support this message.) Divorce rings are a thing (and yes, I have thoughts) And then—because my brain is a pinball machine—we hit a British Vogue trend: divorce ring parties. Women re-setting stones from old engagement rings into new jewelry to mark a fresh chapter. It's community, champagne, and a little "we're going to be okay." Whenever I speak of divorce, I always like to point out that divorce is painful. A broken dream. No matter who's fault it is. Even when it's necessary, it has a long emotional tail. So, if you're in that chapter: I hope you find your next "happily ever after," whatever that looks like. Also: Walking sharks. That's it. That's the sentence. ScienceDaily had me staring into the void with this headline: walking sharks that apparently break rules of reproduction without a measurable increase in energy use. Do I need this information? No. Did I share it anyway? Absolutely. Because that's what I do. Discover stuff and share it. Ozempic marketing, sweatpants history, and the courage to turn on the camera I also touched on: Novo Nordisk leaning into a "Get a Mac"-style ad throwback to clarify Ozempic's FDA-approved uses (marketing is getting very nostalgic lately) International Sweatpants Day, and the fact that sweatpants evolved from athletic wear to "I live here now" fashion (and yes, I did also mention the origins) And threading through all of it was my own little "new era" moment: I turned on a camera in the studio—even though I'm not exactly thrilled about it—because staying relevant means shifting with the times. It means blending wisdom with new tools, learning new stuff, and continuing to show up. Because "The Most Interesting Woman in the World" isn't one person. She's all of us. Especially those of us learning how not to let getting older get in the way of being us.   The Daily Toast (because I always end the show with a little sparkle) I closed with a quote I loved from Dr. Steve Maraboli: "There is nothing more rare, nor more beautiful, than a woman being unapologetically herself…" Amen, Dr. Maraboli. And my personal sign-off still stands: 'Someday' Has Arrived… It's Time to Roll! Onward! Debbie

How do you consistently find high-quality US and European dividend growth stocks? In Episode 285, we revisit our original stock screening framework and update it for today's market environment including AI disruption, insurance sector tailwinds, and dividend safety.Join usFollow Dividend Talk for weekly dividend investing discussions.Join our community on Discord and Facebook, and exploreour premium research at dividendtalk.eu, where we share deep dives and our dividend safety framework.Disclaimer: Educational content only. Not financial advice.Chapters00:00 – Intro & Market Context03:00 – Diageo Dividend Cut07:00 – Dividend Hikes: Munich Re, Allianz & More14:00 – Why European Insurers Are Performing20:00 – How to Find Dividend Growth Stocks 30:00 – Screening Tools for US & European Stocks40:00 – AI, SaaS & Financial Data Debate49:00 – NN Group vs ASR Nederland55:00 – Listener Q&A & Wrap-UpA few links mentioned in this show:The famous CCC-list - US Dividend Aristocrats30 European Dividend StocksFinViz screenerDividend Talk Premium - 150 US & EU dividend stocks assessed for dividend safetyAnother great source is our communities:Dividend Talk @ DiscordDividend Talk @ Facebook

War Kanzler Merz in China gerade der große Pragmatiker – oder wiederholt Deutschland denselben Fehler wie einst mit Russland? Aus dem „systemischen Rivalen“ wird plötzlich der „strategische Partner“, 30 Manager reisen mit, 120 Airbus-Jets sollen gekauft werden. Doch was kommt zurück? Ein Handelsbilanzdefizit von 88 Milliarden Euro bleibt. Im Podcast streiten Bulle Dietmar Deffner und Bär Holger Zschäpitz: Ist Merz' China-Kurs clevere Diplomatie – oder naive Wirtschaftshörigkeit? Was bedeutet das für deutsche Unternehmen? Außerdem: Nordex hebt ab (Gewinn verdoppelt!), Novo Nordisk speckt ab (Abnehm-Pille enttäuscht) – und der Dax gewinnt mit 0,1 Prozent im Fotofinish. Bulle sagt: Jahreshoch kommt. Bär warnt: Das war's mit der Rallye. DEFFNER & ZSCHÄPITZ sind wie das wahre Leben. Wie Optimist und Pessimist. Im wöchentlichen WELT-Podcast diskutieren und streiten die Journalisten Dietmar Deffner und Holger Zschäpitz über die wichtigen Wirtschaftsthemen des Alltags. Schreiben Sie uns an: wirtschaftspodcast@welt.de Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutzerklärung: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a range of transformative events shaping the industry, from regulatory approvals and licensing deals to clinical trial outcomes and strategic partnerships, each carrying profound implications for drug development and patient care.Starting with the biopharma landscape in China, there's a notable shift in the valuation of licensing deals, which have seen a significant increase of 230% in upfront payments. This surge, from $52 million to $172 million between 2022 and early 2026, signals China's growing influence and competitiveness in the sector. Historically considered a low-cost option for licensing deals, China's enhanced innovation capabilities are now attracting Western companies seeking strategic collaborations. The implications are vast, offering Western firms an opportunity to tap into China's expansive market potential and leverage local expertise, underscoring the country's pivotal role in global drug development.In regulatory news, Pfizer's Braftovi (encorafenib) combination therapy has achieved full FDA approval for colorectal cancer treatment. This is a critical development, expanding therapeutic options for a particularly challenging cancer type. The approval highlights the increasing importance of targeted therapies in oncology, reflecting ongoing efforts to address unmet medical needs by enhancing the treatment arsenal available to clinicians. As cancer remains a major global health issue, such advancements are vital for improving patient outcomes.Novartis is making headlines with its substantial investment strategy to boost radiopharmaceutical production capabilities in the United States. With new manufacturing sites planned in Texas and Florida as part of a broader $23 billion investment, Novartis is positioning itself at the forefront of radiopharmaceuticals—a field offering innovative cancer treatments through targeted radiation delivery. This strategic move not only strengthens Novartis's presence in this burgeoning field but also signifies a broader industry trend towards cutting-edge technologies that promise more precise and effective treatment modalities.Shifting focus to drug pricing dynamics, Novo Nordisk has announced plans to reduce list prices for its GLP-1 medications, Ozempic and Wegovy, starting next year. While self-pay channels remain unaffected, this price reduction reflects broader industry trends towards addressing medication costs amidst mounting pressure from healthcare stakeholders. The move aims to enhance affordability for diabetes and obesity treatments, crucial given the rising prevalence of these conditions globally.In gene therapy, BioMarin has faced challenges with its hemophilia A gene therapy, Roctavian. Despite potential clinical benefits, BioMarin's efforts to divest the therapy have resulted in a $240 million financial setback. This scenario underscores the inherent complexities and financial risks associated with developing advanced therapies like gene therapies. Meanwhile, Pfizer has shown continued interest in gene editing technologies by securing global rights to Beam Therapeutics' liver-targeted gene editing candidate. This decision marks Pfizer's strategic pivot towards promising frontiers in therapeutic innovation.Emerging biotech BreezeBio has rebranded and secured $60 million in funding to advance its research in genetic medicine focused on restoring immune tolerance in type 1 diabetes. This strategic pivot towards addressing autoimmune diseases using innovative genetic approaches highlights ongoing efforts within the biotech sector to tackle complex health challenges through cutting-edge science.Collectively, these developments illustrate dynamic trends within the pharmaceutical and biotech sectors: a shift towards more equitable global partneSupport the show

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a compelling array of advancements and strategic shifts that are shaping the healthcare landscape across the globe.In recent times, the pharmaceutical and biotech sectors have showcased remarkable resilience and innovation, driving forward with significant scientific breakthroughs and clinical trial results. A standout achievement comes from Novo Nordisk, whose recent Phase 2 trial results for its triple agonist targeting obesity reported a remarkable weight loss of up to 19.7% in patients over 24 weeks. This promising development positions Novo Nordisk as a formidable contender in the obesity treatment market, potentially affecting giants like Eli Lilly. With obesity being a significant global health challenge, these findings underscore the potential of multi-targeted approaches in managing this complex condition.Regulatory landscapes continue to evolve, with pivotal approvals marking milestones for therapies targeting rare diseases. Immedica Pharma's Loargys received FDA approval for treating hyperargininemia associated with arginase 1 deficiency, highlighting perseverance in overcoming regulatory hurdles after a prior rejection. Additionally, Sanofi and Regeneron's Dupixent achieved its ninth FDA approval, underscoring its versatile potential across multiple indications. These approvals not only reflect regulatory progress but also emphasize the critical role of persistence in drug development.Ethical considerations remain at the forefront of industry discussions, particularly highlighted by Novartis' settlement in a lawsuit concerning the use of Henrietta Lacks' cells without consent. This resolution underscores ongoing ethical challenges within biomedical research, emphasizing the need for ethical vigilance as companies increasingly rely on human-derived materials.Significant business trends are shaping strategic directions within the industry. Pfizer's acquisition of marketing rights for Sciwind's GLP-1 receptor agonist in China exemplifies a calculated move to dominate the obesity treatment market. This strategic acquisition allows Pfizer to leverage China's vast market potential for type 2 diabetes medications and positions it favorably for future weight loss treatments.On the manufacturing front, AbbVie has made substantial investments in U.S. infrastructure, committing $380 million to new North Chicago API plants as part of a decade-long strategy to inject $100 billion into U.S. operations. This initiative highlights a commitment to bolstering domestic production capabilities amidst global supply chain uncertainties.The complexities of drug development are further illustrated by Roche's decision to halt the development of Enspryng for Duchenne muscular dystrophy due to unsatisfactory progress. This shift in focus reflects the inherent challenges of drug repurposing and the necessity of robust clinical evidence to support new indications.Geopolitical factors also play a significant role in shaping industry dynamics, with recent U.S. Supreme Court decisions impacting international trade agreements. Such geopolitical influences can significantly affect pharmaceutical companies' operations and strategic planning.The collaboration between Astellas and Vir Biotechnology reflects another significant trend in strategic partnerships within the industry. Their $1.7 billion deal centered on a novel bispecific T-cell engager for prostate cancer underscores the growing importance of immuno-oncology and innovative approaches to targeting hard-to-treat cancers.The regulatory front continues to see transformative changes with the FDA unveiling draft guidance for a new approval pathway tailored for bespoke gene-editing therapies. This initiative could expedite personalized genetic treatments and transform patSupport the show

Een jaar lang scheten aandeelhouders van Wolters Kluwer in hun broek voor wat er daar aan zat te komen. Het verdienmodel van het databedrijf zou onderuit gehaald worden door AI-bedrijven die het allemaal beter en sneller gaan kunnen. Waardoor de beurskoers in een jaar tijd met ruim 60 procent daalde. Alleen... dat blijkt nu behoorlijk paniekvoetbal. De kwartaalcijfers laten namelijk een ander beeld zien. Omzet en winst stijgen. En Wolters Kluwer bewijst het ongelijk van beleggers nog even extra: want vooral de cloud-activiteiten groeien hard, met 15 procent. Een afscheid in stijl voor ceo Nancy McKinstry, wiens laatste kwartaal dit was. Deze aflevering kijken we of aandeelhouders die zijn vertrokken, nu reden hebben om terug te keren.Hebben we het ook over een ander beursdrama, maar dan in Denemarken. Dat van Novo Nordisk. De maker van onder meer Ozempic had een voorsprong met hun afvalmedicatie, maar werd keihard ingehaald door de concurrentie. En zag het aandeel zelf op een crashdieet gaan. Van het meest waardevolle Europese beursbedrijf, naar een van de beurslosers. Maar die tijd is misschien wel voorbij, want Novo Nordisk heeft iets verzonnen. Het gaat de prijzen halveren.Hoor je ook meer over de State of the Union. Trumps speech heeft een record gebroken. Nog nooit duurde dat politieke praatje zo lang. Maar of het ook een beetje inhoudelijk was, dat bespreken we deze aflevering. Zo wil Trump de inkomstenbelasting inruilen voor.... tarieven! Te gast: Martine Hafkamp van Fintessa Vermogensbeheer BNR Beurs is een journalistiek onafhankelijke productie, mede mogelijk gemaakt door Saxo. Over de makers: Jelle Maasbach is presentator van BNR Beurs en freelance financieel journalist. Zijn favoriete aandeel om over te praten is Disney, maar daar lijkt hij de enige in te zijn. Sinds de eerste uitzending van BNR Beurs is 'ie er bij. Maxim van Mil is presentator van BNR Beurs en journalist bij BNR, waar hij zich focust op de financiële markten en ontwikkelingen in de tech-wereld. Je krijgt hem het meest enthousiast als hij kan praten over ASML, of oer-Hollandse bedrijven zoals Ahold of ABN Amro. Jorik Simonides is presentator van BNR Beurs, economieredacteur en verslaggever bij BNR. Hij wordt er vooral blij van als het een keer níet over AI gaat. Milou Brand is presentator van BNR Beurs, freelance podcastmaker en columnist bij het Financieele Dagblad. Jochem Visser is presentator van BNR Beurs, maakt Beursnerd XL en de podcast Onder Curatoren. Vraag hem naar obscure zaken op financiële markten en hij vertelt je waarom het eigenlijk nóg leuker is dan je al dacht. Over de podcast: Met BNR Beurs ga je altijd voorbereid de nieuwe beursdag in. We praten je in een kleine 25 minuten bij over alle laatste ontwikkelingen op de handelsvloer. We blijven niet alleen bij de AEX of Wall Street, maar vertellen je ook waar nog meer kansen liggen. En we houden het niet bij de cijfers, maar zoeken ook iedere dag voor je naar duiding van scherpe gasten en experts. Of je nu een ervaren belegger bent of net begint met je eerste stappen op de beurs, de podcast biedt waardevolle inzichten voor je beleggingsstrategie. Door de focus op zowel de korte termijn als de lange termijn, helpt BNR Beurs luisteraars om de ruis van de markt te scheiden van de essentie. Van Musk tot Microsoft en van Ahold tot ASML. Wij vertellen je wat beleggers bezighoudt, wie de markten in beweging zet en wat dat betekent voor jouw beleggingsportefeuille.See omnystudio.com/listener for privacy information.

Ihr kriegt aktuell 25 € vom Scalable-ETF, wenn ihr ein neues Konto eröffnet und nutzt. Dazu unterstützt ihr auch noch diesen Podcast. Mehr Infos gibt's hier. Meta kauft AMD-Chips für Milliarden. Anthropic stellt Plug-Ins vor, Salesforce und Co. profitieren. Home Depot wächst online zweistellig. Keysight mit starkem Ausblick. Novo Nordisk halbiert Wegovy-Preis. MTU wird Erwartungen nicht gerecht. Elmos +40% YTD. JPMorgan (WKN: 850628) eröffnet 160 neue Filialen und will 15% aller US-Privatkundeneinlagen halten. Auch PNC (WKN: 867679) setzt auf Expansion. Sterben Bankfilialen doch nicht aus? Jungheinrich (WKN: 621993) kämpft mit chinesischer Konkurrenz und internem Familienstillstand. Gleichzeitig läuft der Umbau zum Tech-Konzern. Schafft die gelbe Ameise die Verdopplung auf 10 Mrd. € Umsatz? Diesen Podcast vom 25.02.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Send a textThis episode unpacks Novo's aggressive price cuts, Lilly's head to head trial win, and the emerging triple agonist race, revealing how pricing strategy and next generation data are colliding in a full scale GLP-1 market war.00:00 – Cold Open: Lilly vs Novo Shock TimingDave opens with the bombshell that Novo funded a tirzepatide trial while simultaneously announcing major price cuts to Wegovy and Ozempic, setting up a strategic chess match.03:20 – Novo Nordisk Price Cuts ExplainedDeep dive into Novo's plan to cut list prices by up to 50% and what that actually means for formulary power, PBMs, and competitive positioning.07:25 – Tirzepatide vs Semaglutide Head to Head TrialBreakdown of the direct comparison study showing stronger weight loss with tirzepatide and what that means clinically and commercially.11:55 – Market Reaction and Strategic ImplicationsDiscussion of stock movement, competitive signaling, and how Novo's pricing move may blunt Lilly's trial victory.14:25 – Novo Triple Agonist Data DropsShift into Novo's early phase data on its triple agonist candidate and how it compares conceptually to existing dual agonists.16:00 – Comparing Novo's Triple to RetatrutideAnalysis of weight loss percentages versus Lilly's retatrutide data and the caution required when comparing across trials.18:15 – The Triple Agonist EraBroader conversation about whether triple agonism consistently pushes weight loss higher and what durability may look like long term.20:00 – Clinical Trial Results vs Real World RealityReminder that clinical trial outcomes do not automatically translate to everyday patient experience.22:30 – Data Refresher on Allurion Ballon ApprovalQuick recap of the headline numbers and strategic landscape as innovation and pricing Visit TRYSHED.COM to learn more today! Use CODE OTP25 to save 25%!

Es ergibt wenig Sinn, Verluste immer weiter anwachsen zu lassen. Wenn ich eine Aktie im Portfolio habe, die lange gut gelaufen ist, und sie plötzlich fällt – soll ich wirklich zusehen, wie die Gewinne wieder verschwinden? Und wenn ich eine Aktie gerade erst gekauft habe und sie direkt danach ins Minus rutscht: Ist einfaches Halten dann sinnvoll? Nehmen wir Novo Nordisk als Beispiel: Über Jahre stieg die Aktie nahezu ununterbrochen, bis sie es eben nicht mehr tat. Wäre es da nicht klug gewesen, bei minus dreißig oder minus fünfzig Prozent die Reißleine zu ziehen? So denken die meisten Anleger – und das ist nachvollziehbar. Gewinne wieder abzugeben oder eine Aktie immer weiter fallen zu sehen, fühlt sich falsch an. Der Impuls dahinter ist also verständlich. Trotzdem müssen wir genauer hinschauen. Denn zwischen Emotion und Strategie liegt ein großer Unterschied. Deshalb geht es heute darum, wie man aus einer langfristigen Position richtig und planvoll aussteigt.
 ► Hole dir jetzt deinen Zugang zur brandneuen BuyTheDip App! Jetzt anmelden & downloaden: http://buy-the-dip.de
 ► An diese E-Mail-Adresse kannst du mir deine Themen-Wünsche senden: podcast@lars-erichsen.de
 ► Meinen BuyTheDip-Podcast mit Sebastian Hell und Timo Baudzus findet ihr hier: https://buythedip.podigee.io
 ► Schau Dir hier die neue Aktion der Rendite-Spezialisten an: https://www.rendite-spezialisten.de/aktion
 ► TIPP: Sichere Dir wöchentlich meine Tipps zu Gold, Aktien, ETFs & Co. – 100% gratis: https://erichsen-report.de/
 Viel Freude beim Anhören. Über eine Bewertung und einen Kommentar freue ich mich sehr. Jede Bewertung ist wichtig. Denn sie hilft dabei, den Podcast bekannter zu machen. Damit noch mehr Menschen verstehen, wie sie ihr Geld mit Rendite anlegen können.
 ► Mein YouTube-Kanal: http://youtube.com/ErichsenGeld
 ► Folge meinem LinkedIn-Account: https://www.linkedin.com/in/erichsenlars/
 ► Folge mir bei Facebook: https://www.facebook.com/ErichsenGeld/
 ► Folge meinem Instagram-Account: https://www.instagram.com/erichsenlars
 Die verwendete Musik wurde unter www.soundtaxi.net lizenziert. 
Ein wichtiger abschließender Hinweis: Aus rechtlichen Gründen darf ich keine individuelle Einzelberatung geben. Meine geäußerte Meinung stellt keinerlei Aufforderung zum Handeln dar. Sie ist keine Aufforderung zum Kauf oder Verkauf von Wertpapieren.
 Zum Zeitpunkt der Erstellung dieses Beitrags war der Autor, Lars Erichsen, in folgenden der besprochenen Finanzinstrumente selbst investiert: Amazon, Novo Nordisk. Geplante Änderungen: Keine. Weitere Informationen entnehmen Sie bitte unserem Transparenzhinweis zum Umgang mit Interessenskonflikten: https://www.lars-erichsen.de/transparenz-und-rechtshinweis

Over 1.5million adults in the UK tried weight loss drugs in 2024-25. Many swear by them, but they have been associated with side effects including nausea and, in some cases, extremely painful gallstones. But what does the evidence actually tell us, and what is the wider impact on the way we view our bodies in society?James Gallagher is joined by Professor of Cardiometabolic Medicine at the University of Glasgow Naveed Sattar, Dr Beverley O'Hara, Lecturer in Public Health Nutrition at Leeds Beckett University, and Dr Margaret McCartney, resident Inside Health GP. They discuss what the evidence tells us about the potential known side effects of these weight loss drugs, and the potential impact their use has on our view of obesity as a society. We also hear from Sarah Le Brocq, who has struggled with obesity all her adult life and has been on these drugs for the past 2-3 years about her experiences. Margaret McCartney has no conflicts of interest to declare.Beverley O'Hara has no conflicts of interest to declare. She has 2 roles with the Association for the Study of Obesity (voluntary academic positions).Naveed Sattar has consulted for and/or received speaker honoraria from AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Carmot Therapeutics, Eli Lilly, Gan & Lee, GlaxoSmithKline, Hanmi Pharmaceuticals, Kailera, Mass Medicines, Menarini-Ricerche, Metsera, Novo Nordisk, Pfizer, Regeneron, Roche, UCB Pharma, and Verdiva Bio; and received grant support paid to his University from AstraZeneca, Boehringer Ingelheim, Novartis, and Roche.Presenter: James Gallagher Producer: Hannah Fisher Researcher: Tom Hunt Production coordinator: Stuart Laws Content Editor: Ilan Goodman

Are you looking to save time, make money, and start winning with less risk? Then head to https://www.ovtlyr.com.The market is getting absolutely hammered right now. Down hard. Sectors bleeding. Headlines screaming about tariffs, inflation, and chaos. And while everyone is debating macro narratives and drawing fancy patterns on charts, there's one simple question that actually matters:Is price going up… or down?In this video, we break down the S&P 500 sell signals, the Nasdaq weakness, tariff uncertainty, rising inflation data, and why chasing “technical bottoms” in collapsing stocks like Novo Nordisk can wreck your portfolio.This is not about predicting the future. It's about responding to what's happening now.While others argue about head and shoulders patterns and magical support lines, this breakdown focuses on direction, trend, and discipline. Because the only time you get paid in the market is when price is moving up. Period.Here's what gets exposed:✅ Why sitting in cash is sometimes the smartest move✅ The truth about market sell signals and trend direction✅ How tariff uncertainty and inflation are pressuring stocks✅ Why buying 70% drawdowns is not a strategy✅ How OVTLYR flags danger before portfolios get wreckedThere's a powerful lesson here about simplicity. You do not need to track the dollar, the 10-year yield, Japan carry trades, or macro noise to be profitable. You need to know when the market is working and when it is not.Right now? It is not.OVTLYR is built for moments like this. It removes emotion, filters noise, and gives clear signals so you can avoid getting caught in stage four downtrends while others are “calling bottoms.”If you care about protecting capital, growing your account, and trading with discipline instead of hope, this one matters.Watch closely. Then decide whether you want to predict… or respond.Subscribe to OVTLYR for disciplined trading strategies that actually make sense.

Stemningen omkring de danske aktier synes at være på et nulpunkt, efter et nyt tørt kurshug til medicinalgiganten Novo Nordisk mandag. Efter en stærk start på året er C25-indekset nu nede med 4 pct. i 2026 og nedturen for Novo Nordisk er nu så voldsom, at aktien er nede med 75 pct. fra toppen. Spørgsmålet er, hvor det efterlader investorerne, og om der stadig kan være gode investeringsmuligheder i de danske aktier. Det diskuterer Millionærklubben med chef for danske aktier i Danske Bank Asset Management Esben Saxbeck Larsen og chefanalytiker i Svenssen & Tudborg Lau Svenssen. Vært: Adam GeilSee omnystudio.com/listener for privacy information.

In der heutigen Folge sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über Enttäuschung bei Novo Nordisk, Gileads Milliarden-Move und Übernahmefantasie bei Paypal. Außerdem geht es um Mongo DB, Zscaler, Datadog Doordash, American Express, Mastercard, Visa, Novo Nordisk, Eli Lilly, Gilead, Arcellx, Domino's, IBM, PayPal, BMW, VW, Mercedes-Benz, SAP, Infineon, Cloudflare, Crowdstrike, Zscaler, KKR, Blackstone, Apollo, GE Vernova, L&G Gold Mining ETF (WKN: A12CCL), L&G DAX Daily 2x Short (WKN: A0X8ZS), Amundi Core MSCI USA (WKN: ETF154), iShares MSCI USA (WKN: A0YEDU), SPDR S&P 500 (WKN: A3EUC1), UBS Core S&P 500 (WKN: A41DL0), SPDR S&P 500 Leaders (WKN: A2PSPE), iShares Core MSCI World (WKN: A0RPWH), Ark Innovation ETF (A14Y8H) und SPDR MSCI All Country World IMI (WKN: A1JJTD). Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Der Börsen-Podcast Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into the latest from an industry that continues to break new ground in both scientific innovation and regulatory landscapes. The pharmaceutical and biotech sectors are buzzing with activity as companies engage in bold strategies and face significant challenges in their quest for groundbreaking treatments.A recent event illustrating the high-stakes nature of this industry involves Novo Nordisk and its decision to conduct a head-to-head clinical trial for Cagrisema against Eli Lilly's Zepbound. This trial, which typically occurs post-approval, was conducted at the candidate stage. Novo Nordisk aimed to establish market dominance by proving superiority early on. However, the trial did not go as planned, with Cagrisema failing to outperform Zepbound. This outcome serves as a reminder of the competitive dynamics in early-stage testing and the strategic risks companies are willing to take in their bid for market leadership.Meanwhile, Gilead Sciences has made a bold move with a $7.8 billion investment in Arcellx, focusing on CAR T-cell therapy. This investment highlights Gilead's commitment to advanced cancer treatments, particularly Anito-cel for relapsed or refractory multiple myeloma. CAR T-cell therapies involve modifying a patient's T-cells to target cancer cells more effectively, representing a significant leap forward in oncological treatments. With an FDA decision anticipated by December 2026, Gilead's investment underscores its strategic focus on transformative therapies that could redefine cancer care.In legal news, Regenxbio has secured a notable victory against Sarepta Therapeutics regarding adeno-associated virus (AAV) technology patents. The appeals court ruling in favor of Regenxbio emphasizes the intricate nature of patent law in biotechnology, where innovations often intersect with naturally occurring biological processes. This decision not only solidifies Regenxbio's intellectual property but also sets a precedent for future patent disputes within the sector.On the regulatory front, Vanda Pharmaceuticals has rebounded from previous setbacks by securing FDA approval for drugs targeting bipolar disorder and schizophrenia. This achievement marks a promising shift for Vanda, demonstrating resilience and adaptability in redirecting focus towards neuropsychiatric conditions. The approval expands therapeutic options for these complex disorders, addressing long-standing unmet needs within mental health care.Despite these advancements, some areas continue to face hurdles. Gene therapies like Casgevy and Lyfgenia for sickle cell disease have struggled to gain traction two years post-launch. These therapies promise a one-time cure by correcting genetic defects but have encountered challenges in achieving widespread adoption. The difficulties reflect broader issues in transitioning from clinical success to market viability.Moreover, workforce reductions at major companies such as Bristol-Myers Squibb and Catalent signal structural changes within the industry. These layoffs may indicate shifts in strategic focus or responses to evolving market pressures as companies strive for efficiency and innovation.Regulatory practices are also undergoing scrutiny as the FDA considers defaulting to single clinical trial requirements for drug approvals. While this move could streamline development processes, it raises concerns about maintaining rigorous safety standards—a balance that remains crucial as companies push to bring innovative treatments to market swiftly yet safely.The dynamic nature of this industry is further highlighted by Candel Therapeutics' recent $100 million royalty deal aimed at launching its prostate cancer treatment. This strategic move underscores growing interest in innovative oncology solutions thaSupport the show

Wie steht's um deine Altersvorsorge? Kannst du dir jetzt bei Scalable Capital kostenlos ausrechnen: Mehr dazu hier. Zoll-Chaos drückt Märkte, Gold & China steigen. Wintersturm legt Airlines lahm. Software stürzt weiter. PayPal springt nach Übernahmegerücht. Gilead x Arcellx. Novo Nordisk crasht. Enel investiert. Lambo will kein E-Auto. IQM will an Börse. 20% Wachstum pro Jahr mit simplen Rohrverbindern? Reliance Worldwide (WKN: A2AHE7) dominiert mit der Marke SharkBite 85% des US-Marktes und ist das „Tesa“ der Klempner-Branche. 50% Rendite gab's für Südafrikas Leitindex letztes Jahr. Trotz 31% Arbeitslosigkeit. Wir schauen uns an, welche Rolle Player wie Shoprite (WKN: 853202), Capitec (WKN: 779555) oder Remgro (WKN: 578937) dabei spielen. Diesen Podcast vom 24.02.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Entering the final trading week of February, Carl Quintanilla, Jim Cramer and David Faber explored what's at stake for the markets, especially after Friday's Supreme Court ruling that struck down many of President Trump's reciprocal tariffs — and the president responding with plans to raise global tariffs by 15%. Shares of Novo Nordisk tumbled: Trial results show its next-generation obesity treatment was less effective than the Eli Lilly drug marketed as Zepbound and Mounjaro. Also in focus: The winter storm blasting the Northeast results in more than 10,000 flight cancellations, Alphabet upgraded, software stocks downgraded, AI roundup, Netflix-Warner latest from Ted Sarandos to Susan Rice and Trump. Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Carl Quintanilla, Sara Eisen, and David Faber kicked off a snowy morning with a look at the broader markets, and where tariff rates stand - as stocks take a leg lower following last week's SCOTUS decision. Charles Schwab's Chief Strategist Liz Ann Sonders joined the team with more on what it all means for stocks - before longtime geopolitical expert Ian Bremmer from Eurasia group gave his take on the impact for already-made trade deals. Plus: the 130 billion dollar question... Who will get a tariff refund? Hear a read from the ground with the CEO of Flexport - whose new 'refund calculator' is already getting use from Fortune 500 companies.  Around the edges: details on the trial results hitting Novo Nordisk shares, and the latest on media names as President Trump threatens Netflix over a board member's political comments.  Squawk on the Street Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The Science Behind the New Wegovy Pill (with Novo Nordisk's Dr. Jason Brett)What actually makes a GLP-1 pill work in the real world—and why does taking it come with such specific rules? And if these meds improve health beyond weight, why does the conversation still get stuck on the scale?This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor are joined by Dr. Jason Brett of Novo Nordisk to break down the science behind the newly approved Wegovy pill. They talk about what it takes to deliver a peptide medication orally, what the dosing and day-to-day routine really look like, and why access and pricing remain such a big part of the story. The conversation also zooms out to the bigger point: treating obesity is about improving health outcomes—like liver and cardiovascular risk—not just weight.Key TakeawaysOral semaglutide requires specific formulation technology to survive the stomach and be absorbed at a meaningful level.The “30-minute rule” isn't random—it's part of how the pill has a chance to work as intended.Treating obesity is about improving health outcomes (like liver and heart risk), not just “moving a number on a scale.”Pricing and access shape who can actually benefit, even when the science is strong.Calorie-restriction messaging can backfire for people already dealing with metabolic adaptation and under-nutrition.Notable Quote"Fat Science has no financial relationship with Novo Nordisk. No sponsorship. No consulting fees, no affiliate arrangements. Zero." — Mark WrightLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.

Novo Nordisk Chief Scientific Officer Martin Holst Lange discusses the recent clinical trial results of the company's weight loss obesity shot CagriSema, which delivered less weight loss than Eli Lilly’s tirzepatide. Holst Lange also outlines Novo Nordisk's broader obesity treatment pipeline. He speaks with Bloomberg's Dani Burger. See omnystudio.com/listener for privacy information.

As Ghislaine Maxwell refuses to answer questions from Congress, federal files reveal a new characterization of how much Donald Trump knew about Jeffrey Epstein's misdeeds. Cuba tells airlines they won't be able to refuel in Havana, as US sanctions lead to an oil shortage. And drugmaker Novo Nordisk sues compound pharmacy Hims & Hers over copied weight loss drugs.  Learn more about your ad choices. Visit podcastchoices.com/adchoices

A.M. Edition for Feb. 9. The latest revelations from the Epstein files bring down the top aide to Britain's Prime Minister. Will Keir Starmer be next? WSJ U.K. correspondent Max Colchester weighs in. Plus, Novo Nordisk shares are rallying after the U.S. Food and Drug Administration threatened to restrict access to the ingredients needed for knockoffs of popular GLP-1 medicines like WeGovy. And SpaceX delays its Mars plans to focus on the Moon instead. Luke Vargas hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices

A.M. Edition for Feb. 4. Software stocks are sliding again today, following a rough day on Wall Street that saw the rise of new AI tools shave more than $300 billion off of companies that sell or invest in software. WSJ's Hannah Miao explains what's driving the selloff and what it all means for investors. Plus, Novo Nordisk shares plummet as the weight-loss drugmaker warns of unprecedented pricing pressure. And we look at why China is banning retractable car door handles. Luke Vargas hosts. Sign up for the WSJ's free What's News newsletter. Learn more about your ad choices. Visit megaphone.fm/adchoices